

# Pharmacy & Therapeutics Committee

## Meeting Minutes

Thursday, May 16th, 2024

7:00 a.m. to 8:45 a.m.

Video Call: [meet.google.com/tni-wias-qke](https://meet.google.com/tni-wias-qke)

### Committee Members Present:

Cole Sloan, PharmD, BCPS, BCGP, Committee Chair

Bryan Larson, PharmD, P&T Manager

Rocky Parker, PharmD, MBA

Michelle Hofmann, MD

Susan Siegfried, MD

### Committee Members Excused:

Clayton Grace, RPh

### Dept. of Health/Div. of Health Care Financing Staff Present:

Yoon Kim-Butterfield, MD

Stephanie Byrne, PharmD

Andrea Rico, CphT, CPC

Luis Moreno, PharmD, CDCES

Ngan Huynh, PharmD

### University of Utah Drug Regimen Review Center Staff Presenter:

Valerie Gonzeles PharmD

### Other Individuals Present:

Samantha Eshelman

Alice S

Monet Luloh, PharmD, DRRC

Jason Bott, Lilly

Sara Stolfus, Artia

Meeting conducted by: Cole Sloan, Committee Chair

---

1. **Welcome & Housekeeping:** Cole Sloan announced quorum and opened the meeting.
2. **Review and Approval of**
  - a. **February Minutes:** Bryan Larson made a motion to approve the

# Pharmacy & Therapeutics Committee

## Meeting Minutes

minutes from February 2024. Rocky Parker seconded the motion. All in favor, motion passed.

- b. P&T Committee Bylaws updates:** Bryan Larson presented updated bylaws to the P&T Committee. Updates were necessary to update language since the merger between DOH and DHS to form DHHS. Michelle Hofmann mentioned the need to double check if the P&T meetings will need to have a physical anchor location. Bryan Larson agreed to verify with the Assistant Attorney General (AAG). Michelle Hofmann motioned to approve the proposed updates pending the review by the AAG. Bryan Larson seconded the motion. Unanimous approval.

### 3. **Drug Utilization Review (DUR) Board update:**

Bryan Larson shared the following DUR Board Meeting updates:

- February 2024-Persistence on Sublocade for Opioid Use Disorder: A Retrospective Review
- March 2024 - Gene Therapy for Sickle Cell Disease (Lyfgenia, Casgevy)
- April 2024 - Short Acting Beta 2-Agonist (SABA) utilization
- May 2024 - Montelukast utilization review, and DUR Bylaws update.

### 4. **Topic:**

**Anti-VEGF (Oral)** - axitinib (Inlyta), cabozantinib (Cabometyx, Cometriq), fruquintinib (Fruzaqla), lenvatinib (Levinma), pazopanib (Votrient), regorafenib (Stivarga), sorafenib (Nexavar), sunitinib (Sutent), tivozanib (Fotivda), vandetanib (Calpresa)

- a. Presented by: Valerie Gonzales, PharmD, U of U DRRC
- b. Public Comment: None
- c. Committee Discussion:

Michelle Hofmann asked about the low utilization in the Medicaid Fee-for-service (FFS) population. Valerie Gonzales said that she thinks that these diagnoses are rare and through her research it could be due to Medicaid FFS population not having these diagnoses as much. Michelle Hofmann said the first line therapy recommendation usually is alternative treatments rather than the anti-VEGF, hence the low utilization.

# Pharmacy & Therapeutics Committee

## Meeting Minutes

Susan Siegfroid asked about other states' policies on this class of medications, if they require prior authorization. Bryan Larson said he hasn't looked into other states' policies.

Cole Sloan asked what if the providers want to request medication that is a non-preferred agent or cross use of ophthalmic and oral medications . Bryan Larson said that there will be three (3) different drug classes on the PDL for anti-VEGF: ophthalmic, IV and oral anti-VEGF. And if the provider requests a cross use between the ophthalmic and IV or oral classes and for a non-preferred product, a prior authorization is needed. Review will be based on NCCN guidelines.

Cole Sloan motioned for the inclusion on the PDL, at least one (1) agent from the NCCN recommendation as first line therapy as a preferred product. Bryan seconded the motion. All in favor. Unanimously approved.

Bryan Larson also mentioned that grandfathering is also considered during the prior authorization process. No motion was made regarding grandfathering.

5. **Public Meeting Adjourned:** Cole Sloan motioned to close the meeting. Susan Siegfroid seconded the motion. Unanimous Approval.
6. **Next meeting is scheduled for** September 19, 2024: Hereditary Angioedema

---

Audio recording of all P&T meetings are available online at:  
[https://www.youtube.com/@dmhf\\_webdohdhs2](https://www.youtube.com/@dmhf_webdohdhs2)